---
title: "石藥 SYH2082 注射液獲批美國臨牀"
description: "石藥集團的 SYH2082 注射液已獲得美國 FDA 批准，允許在美國進行臨牀試驗。該藥物為 GLP-1/GIP 受體雙偏向性激動劑，旨在通過選擇性激活 cAMP 通路來提高藥效並延長作用時間，結合長半衰期修飾和長效製劑技術，目標是實現持續減重。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/276035702.md"
published_at: "2026-02-16T06:11:03.000Z"
---

# 石藥 SYH2082 注射液獲批美國臨牀

> 石藥集團的 SYH2082 注射液已獲得美國 FDA 批准，允許在美國進行臨牀試驗。該藥物為 GLP-1/GIP 受體雙偏向性激動劑，旨在通過選擇性激活 cAMP 通路來提高藥效並延長作用時間，結合長半衰期修飾和長效製劑技術，目標是實現持續減重。

石藥集團 (01093.HK) 公佈，集團開發的 GLP -1 / GIP 受體雙偏向性 激動多肽長效注射液 (SYH2082 注 射液) 已獲得美國食品藥品監督管理局批准，可在美國開展臨牀試驗。

集團指，SYH2082 可選擇性激活 c AMP 通路，降低β-arrestin 募集，從而減少受體內吞及脱敏，提升藥效並延長作用持續時間。同時，SYH2082 結合長半衰期修飾平台技術和長效製劑平台技術，旨在實現給藥間隔內的持續減重。

### Related Stocks

- [01093.HK - 石藥集團](https://longbridge.com/zh-HK/quote/01093.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | [Link](https://longbridge.com/zh-HK/news/276056763.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-HK/news/276035104.md) |
| Did Global Partners' (GLP) Higher Quarterly Payout Just Recast Its Income-Focused Investment Narrative? | Global Partners LP announced a cash distribution of $0.7600 per unit for Q4 2025, payable on February 13, 2026. This dec | [Link](https://longbridge.com/zh-HK/news/275927197.md) |
| CSPC Pharma Says Glp-1/Gip Receptor Dual-Biased Agonist Polypeptide Injection Obtains Approval In U.S. | CSPC Pharmaceutical :GLP-1/GIP RECEPTOR DUAL-BIASED AGONIST POLYPEPTIDE INJECTION (SYH2069 INJECTION) OBTAINS CLINICAL T | [Link](https://longbridge.com/zh-HK/news/268776894.md) |
| 05:36 ETSunlight.com Survey: GLP-1 Weight Loss Is Changing Dating and Relationships | A survey by Sunlight.com reveals that GLP-1 weight loss medications significantly impact dating and relationships. The s | [Link](https://longbridge.com/zh-HK/news/275442014.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。